RecruitingPhase 4NCT07150624

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

Polyene Phosphatidylcholine Injection for the Treatment of Perioperative Liver Injury With Laparoscopic Hemihepatectomy in Hepatocellular Carcinoma: a Multicenter Randomized Controlled Study


Sponsor

Anhui Provincial Hospital

Enrollment

96 participants

Start Date

Aug 30, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hemihepatectomy for hepatocellular carcinoma were compared.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a drug called polyene phosphatidylcholine helps protect the liver from injury after major liver surgery (liver resection) for liver cancer (hepatocellular carcinoma, or HCC). Liver injury is a common complication of this surgery, and researchers are looking for ways to reduce it. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with liver cancer (a single HCC tumor less than 10 cm, with no spread to other organs) - You are scheduled to have a laparoscopic liver resection (minimally invasive liver surgery) - Your liver function is good (Child-Pugh grade A or B, score ≤7) - Your BMI is between 18.5 and 28 **You may NOT be eligible if...** - Your liver function is poor - You have multiple tumors or cancer that has spread beyond the liver - You have a condition that makes surgery too risky Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGExperimental Group

Receiving 930mg of polyene phosphatidylcholine injection one day before the operation,twice a day. And 930mg of polyene phosphatidylcholine injection,twice a day, combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation.

DRUGcontrol group

Receiving 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation.


Locations(1)

Anhui Provincial Hospital

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07150624


Related Trials